These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 25531940

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF.
    Cochrane Database Syst Rev; 2020 Oct 27; 10(10):CD007004. PubMed ID: 33107592
    [Abstract] [Full Text] [Related]

  • 3. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
    Bianchi S, Bigazzi R, Campese VM.
    Kidney Int; 2006 Dec 27; 70(12):2116-23. PubMed ID: 17035949
    [Abstract] [Full Text] [Related]

  • 4. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF.
    Cochrane Database Syst Rev; 2014 Apr 29; (4):CD007004. PubMed ID: 24782282
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
    Surabenjawong U, Thunpiphat N, Chatsiricharoenkul S, Monsomboon A.
    J Med Assoc Thai; 2013 Aug 29; 96(8):905-10. PubMed ID: 23991595
    [Abstract] [Full Text] [Related]

  • 7. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease.
    Guney I, Selcuk NY, Altintepe L, Atalay H, Başarali MK, Büyükbaş S.
    Ren Fail; 2009 Aug 29; 31(9):779-84. PubMed ID: 19925284
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
    An J, Niu F, Sim JJ.
    Pharmacotherapy; 2021 Dec 29; 41(12):998-1008. PubMed ID: 34655484
    [Abstract] [Full Text] [Related]

  • 13. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B.
    Clin J Am Soc Nephrol; 2006 Sep 29; 1(5):940-51. PubMed ID: 17699311
    [Abstract] [Full Text] [Related]

  • 14. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep 29; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 15. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N, Kalaitzidis R, Bakris GL.
    Am J Nephrol; 2009 Sep 29; 30(5):418-24. PubMed ID: 19738369
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
    González Monte E, Andrés A, Polanco N, Toribio MJ, Santana R, Gutiérrez Martínez E, González J, Ramírez E, Hernández A, Morales E, Praga M, Morales JM.
    Transplant Proc; 2010 Oct 29; 42(8):2899-901. PubMed ID: 20970564
    [Abstract] [Full Text] [Related]

  • 18. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
    Bianchi S, Bigazzi R, Campese VM.
    Am J Kidney Dis; 2010 Apr 29; 55(4):671-81. PubMed ID: 20097461
    [Abstract] [Full Text] [Related]

  • 19. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH, Peters CD, Christensen JH, Birn H.
    BMJ Open; 2022 Feb 21; 12(2):e057503. PubMed ID: 35190442
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.